Vivos (RDGL) Stock Overview
A radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
RDGL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Vivos Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.082 |
| 52 Week High | US$0.17 |
| 52 Week Low | US$0.043 |
| Beta | -0.64 |
| 1 Month Change | -0.20% |
| 3 Month Change | 16.63% |
| 1 Year Change | -14.91% |
| 3 Year Change | 16.80% |
| 5 Year Change | -3.95% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| RDGL | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.2% | 1.0% | 3.4% |
| 1Y | -14.9% | -6.6% | 29.7% |
Return vs Industry: RDGL underperformed the US Medical Equipment industry which returned -9.4% over the past year.
Return vs Market: RDGL underperformed the US Market which returned 25.7% over the past year.
Price Volatility
| RDGL volatility | |
|---|---|
| RDGL Average Weekly Movement | 7.5% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: RDGL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RDGL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1 | Mike Korenko | radiogel.com |
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. The company develops an yttrium-90 based precision radionuclide therapy device; RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing a universal laboratory cooling device; hydrogel; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Precisiongel names.
Vivos Inc. Fundamentals Summary
| RDGL fundamental statistics | |
|---|---|
| Market cap | US$40.74m |
| Earnings (TTM) | -US$3.07m |
| Revenue (TTM) | US$68.38k |
Is RDGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDGL income statement (TTM) | |
|---|---|
| Revenue | US$68.38k |
| Cost of Revenue | US$128.13k |
| Gross Profit | -US$59.75k |
| Other Expenses | US$3.01m |
| Earnings | -US$3.07m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0064 |
| Gross Margin | -87.39% |
| Net Profit Margin | -4,483.86% |
| Debt/Equity Ratio | 0% |
How did RDGL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 03:49 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vivos Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.